Posts by SebastianFeye


Over-the-Counter (OTC) drug monographs represent current regulatory standards for the marketing of non-prescription drug products not covered by new drug applications. These standards provide the marketing conditions for some OTC drug products including the active ingredients, labeling, and other general requirement in the US, OTC drug medicines making up around 60% of all medicines (Prescription (Rx) and Non-Prescription). Developed...

Read More

Due to the COVID-19 pandemic, world-wide demand has soared for hand sanitizer and anti-viral products. Below, we outline five basic steps for domestic and foreign manufacturers or domestic distributors who want to get their drug product into the US market but never dealt with the FDA’s electronic drug registration and listing. The scope of products includes: Rx (Prescription Drugs) and OTC (Over the counter) – ex. Hand Sanitizer,...

Read More

Due to the novel coronavirus/SARS-CoV-2/COVID-19 rapid infection rate, as well the viruses ability to create asymptomatic carriers, resulting in major societal disruptions and shutdowns have occurred throughout the world, but nowhere has this pandemic hit hardest than within the health care systems, hospitals and clinics. Due to the enormous surge of critical care, there is a massive demand and shortage of Personal Protective...

Read More

A very informative and detailed overview of the SARS-CoV-2 or novel Coronavirus from a Stanford Doctor, Michael Lin, as well as a bonus recipe at end for making hand sanitizer. Links referenced in Slides Slide 3: https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htmSlide 4: https://abcnews.go.com/Health/covid19-days-surfaces-experiment-findings/story%3Fid=69569397Slide 5:...

Read More

This blog post was written following a ReedTech webinar (dated 11.7.2019) which focused on helping companies understand how to navigate the state of Cannabidiol (CBD) regulatory environment. This post is for informative purposes only and to provide guidance to minimize risks when labeling, promoting and selling cannabis-derived products in the US. To date, FDA has approved only one CBD drug product developed by GW Pharmaceuticals Inc...

Read More